ARCHIVES

Nexavar Phase III Trial Fails To Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Politics, Short Tempers, Grievances Dominate NIH Panel On Unconventional Medical Practices

September 25, 1992

ACS Community Demonstration Projects Complete, Reach Target Populations, Teach Many Lessons

June 25, 1993

Risk Assessment Key In Long-Term Treatment

August 29, 2008

First Report On Carcinogens Now Avaiable

October 3, 1980

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

April 17, 2009

Late Effects In Breast Cancer Treatment Found In Study

January 25, 2002